Indian Drug Companies Increasingly Active In Global M&A
This article was originally published in The Pink Sheet Daily
Subcontinent’s pharmaceutical companies are “getting very ambitious,” Ranbaxy exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY
Under expansion of 2003 deal, Indian firm will take targets to proof of concept, gaining milestones, possible royalties.
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.